Open access peer-reviewed Edited Volume

Update on Hepatitis C

Luis Rodrigo

University of Oviedo

Dr. Luis Rodrigo MD, Emeritus Professor of Medicine at the University of Oviedo (Spain). He has been the Chief of Gastroenterology Service at the HUCA Hospital in Oviedo for more than 40 years and has contributed actively to the formation of approximately 100 specialists in gastroenterology.

Covering

Diabetic Nephropaty Glomerulonephritis Direct-Acting Antivirals Combinations Primary Care Physicians Antiviral Agents World Health Organization Virus B Global Vaccination DAA Efficacy Pegylated Interferon Drug Therapy Health Care Costs

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Infection with Hepatitis C virus (HCV) leads to an asymptomatic acute stage. However, approximately 75% of acutely infected patients face a substantial risk of developing chronic HCV infection. During the 2 decades after infection, 27% develop liver cirrhosis, and 25% develop hepatocellular carcinoma (HCC). Worldwide, an estimated 71 million people were living with chronic HCV infection (1.0% of the global population). Whilst, in the European Union/European Economic Area (EU/EEA), it was estimated that more than 14 million people were living with chronic HCV infection, suggesting a relatively higher prevalence of 1.5% in this area.

The primary goal of diagnostic testing is to identify and link infected individuals to appropriate treatment. Several modelling studies suggest that scaling up an HCV treatment can lead to substantial reductions in anti-HCV prevalence and reduce transmission. Anti-HCV antibodies are detectable by enzyme immunoassay (EIA) in the vast majority of patients with an HCV infection. In addition, rapid diagnostic tests (RDTs) are also recommended in settings where there is limited access to laboratory infrastructure and testing or populations where access to RDTs would facilitate linkage to care.

The introduction of direct-acting antivirals (DAAs) has been a major breakthrough in the treatment of hepatitis C. However, the high acquisition costs of sofosbuvir-based regimens limit the access for patients and influence the costs of healthcare resource utilization in hepatitis C. It is important to have the latest estimates of prevalence, especially in high-risk groups, for cost of illness, cost-effectiveness and the budget of impact studies.

Publishing process

Book initiated and editor appointed

Date completed: August 31st 2020

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline Extended: Open for Submissions

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Approved chapters written in full and submitted

Deadline for full chapters: November 27th 2020

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: February 15th 2021

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: April 16th 2021

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Luis Rodrigo

University of Oviedo

Luis Rodrigo, MD, is Emeritus Professor of Medicine at the University of Oviedo, Spain. He has been Chief of Gastroenterology Service at HUCA Hospital in Oviedo for more than 40 years. He obtained a PhD in 1975 and has had a long teaching and research career. He has published 590 scientific papers in both English and Spanish and written thirty-five book chapters and edited twenty-four books. Dr. Rodrigo has participated as a main investigator in forty-five clinical trials. He has directed forty doctoral theses and contributed to the formation of 100 specialists in gastroenterology working in hospitals in Spain and abroad. His areas of interest are celiac disease and autoimmune diseases.

View profile

Book chapters authored 4

Books edited 14

Introducing your Author Service Manager

Ms. Dolores Kuzelj

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire